Jamshedpur Reporter

Benign Prostatic Hyperplasia Market Report 2032:- Latest FDA, EMA, PDMA, Pipeline Therapies, Epidemiology

 Breaking News
  • No posts were found

Benign Prostatic Hyperplasia Market Report 2032:- Latest FDA, EMA, PDMA, Pipeline Therapies, Epidemiology

June 10
20:30 2024
Benign Prostatic Hyperplasia Market Report 2032:- Latest FDA, EMA, PDMA, Pipeline Therapies, Epidemiology

DelveInsight’s “Benign Prostatic Hyperplasia Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the Benign Prostatic Hyperplasia, historical and forecasted epidemiology as well as the Benign Prostatic Hyperplasia market trends in the United States, EU4 (Germany, Spain, Italy, France), and the United Kingdom, and Japan.

Explore the intricate details of the Benign Prostatic Hyperplasia Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Benign Prostatic Hyperplasia Market Forecast. Click here to stay ahead in healthcare innovation @ Benign Prostatic Hyperplasia Market Size

Key Takeaways from the Benign Prostatic Hyperplasia Market Report

  • April 2024:- RDC Clinical Pty Ltd- A Study to Compare 2 Extracts of Saw Palmetto Versus Placebo on the Symptoms of Beni. A randomized, double-blind, placebo-controlled, parallel group study to compare 2 extracts of saw palmetto versus placebo on the symptoms of benign prostate hyperplasia (BPH) in 120 generally healthy participants, 45 – 80 years.
  • February 2024:- EMS- Phase III, Multicenter, Randomized, Double-blind Clinical Trial to Assess the Efficacy and Safety of the DTT106 in the Treatment of Erectile Dysfunction Associated With Benign Prostatic Hyperplasia. The purpose of this study is to assess the safety and efficacy of the DTT106 in the treatment of erectile dysfunction associated with benign prostatic hyperplasia.
  • As per a study conducted by Lim et al. (2017), the histological prevalence of BPH was observed as 8%, 50%, and 80% in the 4th, 6th, and 9th decades of life, respectively.
  • As per the article by Nash et al. (2010), general practitioners in the UK will, on average, each have 50 men on their list between the ages of 60‒80 years who have moderate or severe urinary symptoms related to BPH.
  • The leading Benign Prostatic Hyperplasia Companies such as Allergan PLC, Eli Lilly & Company, Boehringer Ingelheim, Merck & Co. Inc., Astellas Pharma Inc., Olympus Medical, Butterfly Medical, SRS Medical, Teleflex Interventional Urology, Urotronic, Zenflow, ProArc Medical, Medion Biodesign, and others.
  • Promising Prostatic Hyperplasia Therapies such as Saw palmetto extract 320mg per day, Commercial Saw palmetto extract 320mg per day, Tanzânia association, DTT106, and others.

Delve deep into the Benign Prostatic Hyperplasia Market Landscape: Analyze drug adoption, treatment paradigms, and epidemiological shifts in our detailed Benign Prostatic Hyperplasia Market Forecast. Click here to shape the future @ Benign Prostatic Hyperplasia Epidemiology Insights

Benign Prostatic Hyperplasia Overview

Benign prostatic hyperplasia—also called BPH—is a condition in men in which the prostate gland is enlarged and not cancerous. Benign prostatic hyperplasia is also called benign prostatic hypertrophy or benign prostatic obstruction. As the prostate enlarges, the gland presses against and pinches the urethra. The bladder wall becomes thicker. Eventually, the bladder may weaken and lose the ability to empty completely, leaving some urine in the bladder. The narrowing of the urethra and urinary retention—the inability to empty the bladder completely—cause many of the problems associated with benign prostatic hyperplasia.

Benign Prostatic Hyperplasia Epidemiology Insights

BPH is the most common prostate problem for men older than age 50. Men of age ≥40 years with or without family history of BPH; medical conditions such as obesity, heart and circulatory disease and type 2 diabetes; lack of physical exercise, and erectile dysfunction are more likely to develop BPH.

  • Total Benign Prostatic Hyperplasia Prevalent Cases
  • Benign Prostatic Hyperplasia Age-specific Prevalent Cases
  • Benign Prostatic Hyperplasia Diagnosed and Treatable Cases

Navigate the complexities of the Benign Prostatic Hyperplasia Market: gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Benign Prostatic Hyperplasia Market Forecast. Click here to get more insights @ Benign Prostatic Hyperplasia Treatment Market

Benign Prostatic Hyperplasia Treatment Market Landscape

The Benign Prostatic Hyperplasia treatment includes watchful waiting, medical therapies, minimally invasive surgery, andsurgery. Watchfulwaiting is the recommended strategy for patients with BPH who have mild symptoms and for those with moderate-tosevere symptoms who are not bothered by their symptoms and are not experiencing complications of BPH. Medical therapies for the treatment of BPH include alpha-blockers, phosphodiesterase-5 inhibitors, 5-alpha reductaseinhibitors, and combination medications. The smooth muscle tension is mediated by alpha-1-adrenergic receptors; hence, alpha-adrenergic receptor–blockingagents relax the smooth muscle, thus allowing easier passage of urine. Based on the receptor subtype selectivity and theduration of serum elimination half-lives, they are categorized into nonselective alpha-blockers (phenoxybenzamine),selective short-acting alpha-1 blockers (prazosin, alfuzosin, indoramin), selective long-acting alpha-1 blockers (terazosin,doxazosin, slow-release alfuzosin), and partially subtype (alpha-1a)–selective agents (tamsulosin (Flomax), silodosin(Rapaflo)).

Benign Prostatic Hyperplasia Drug Market

The key driver for the Benign Prostatic Hyperplasia drug market is an increase in the cases of risk factors such as obesity, heart and circulatory disease, type 2 diabetes, a rise in the geriatric population along with the expected approval of emerging therapies such as Vibegron (Urovant Sciences ), GV1001 (GemVax & KAEL ) and AUS-131 (Ausio Pharmaceuticals) . The pipeline for Benign Prostatic Hyperplasia brings a positive ray of hope for a better treatment pattern in the market in the upcoming years.

Benign Prostatic Hyperplasia Emerging Therapy Assessment

Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as GemVax & KAEL, Urovant Sciences, Ausio Pharmaceuticals, etc., are developing therapies for the Benign Prostatic Hyperplasia treatment.

Benign Prostatic Hyperplasia Drugs Uptake

  • GemVax & KAEL is developing GV1001 for the treatment of BPH. GV1001 is telomerase derived peptide that is composed of 16 amino acids. Telomerase is known to have various functions such as immune anticancer effect, antiinflammatory, antioxidant and cell protection effect, in addition to its unique function of maintaining the length of telomeres present at the end of chromosomes. The treatment of the final patient in the phase II BPH clinical trial was completed in October 2016. The results of the trial, confirmed both the feasibility of treating benign prostatic hyperplasia and the safety relative to preexisting solutions. The company is currently evaluating it in phase III clinical study to evaluate the efficacy and safety of GV1001 (0.56 mg and 1.12 mg) administered as a treatment for BPH.
  • Urovant Sciences are developing Vibegron for the treatment of BPH. Vibegron is an oral, once-daily, small molecule beta-3 agonist. The beta-3 adrenergic receptor is the most prevalent beta-adrenergic receptor subtype on the smooth muscle around the bladder. The FDA approved vibegron in December 2020 for the treatment of adult patients with OAB with symptoms of urge urinary incontinence (UUI), urgency, and urinary frequency. The company is currently evaluating it in phase III clinical trials in men With overactive bladder (OAB) symptoms on pharmacological therapy for BPH for which results are expected.
  • Ausio Pharmaceuticals has completed a phase II clinical trial of AUS-131 (Sequo) for the treatment of BPH. AUS-131 is a first-in-class, nonsteroidal, nonhormonal, small molecule (S-equol) that has higher selectivity toward estrogen receptor β (ERβ) than to estrogen receptor alpha (ERα).

Unlock insights into the Benign Prostatic Hyperplasia Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Benign Prostatic Hyperplasia Market Forecast. Click here @ Benign Prostatic Hyperplasia Market Drivers and Barriers

Scope of the Benign Prostatic Hyperplasia Market Report

  • Coverage- 7MM
  • Benign Prostatic Hyperplasia companies- Allergan PLC, Eli Lilly & Company, Boehringer Ingelheim, Merck & Co. Inc., Astellas Pharma Inc., Olympus Medical, Butterfly Medical, SRS Medical, Teleflex Interventional Urology, Urotronic, Zenflow, ProArc Medical, Medion Biodesign, and others.
  • Benign Prostatic Hyperplasia Therapies- Saw palmetto extract 320mg per day, Commercial Saw palmetto extract 320mg per day, Tanzânia association, DTT106, and others.
  • Benign Prostatic Hyperplasia Market Dynamics: Benign Prostatic Hyperplasia Market drivers and Benign Prostatic Hyperplasia Market Barriers
  • Benign Prostatic Hyperplasia Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Benign Prostatic Hyperplasia Unmet Needs, KOL’s views, Analyst’s views, Benign Prostatic Hyperplasia Market Access and Reimbursement

Gain a strategic edge in the Benign Prostatic Hyperplasia Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Benign Prostatic Hyperplasia Market Forecast. Click here to lead in advancements @ Benign Prostatic Hyperplasia Clinical Trials Assessment

Table of Content

1. Report Introduction

2. Executive Summary of Benign Prostatic Hyperplasia (BPH)

3. Benign Prostatic Hyperplasia (BPH) Market Share at a glance

4. Disease Background and Overview

5. Patient Journey

6. Epidemiology and Patient Population

7. Country Wise: Epidemiology of Benign Prostatic Hyperplasia (BPH)

8. Current Treatment and Medical Practices

9. Marketed Drugs

10. Unmet Needs of BPH

11. Emerging Therapeutics

12. Market Size of Benign Prostatic Hyperplasia (BPH)

13. Region-Wise Market size of Benign Prostatic Hyperplasia (BPH)

14. Market Drivers

15. Market Barriers

16. SWOT Analysis

17. KOL Views

18. Reimbursement and Market Access

19. Appendix

20. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/